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Abstract
Background: We conducted a phase I, randomized, double-blind, placebo-controlled trial to assess the safety and
immunogenicity of escalating doses of two recombinant replication defective adenovirus serotype 35 (Ad35) vectors
containing gag, reverse transcriptase, integrase and nef (Ad35-GRIN) and env (Ad35-ENV), both derived from HIV-1 subtype
A isolates. The trial enrolled 56 healthy HIV-uninfected adults.
Methods: Ad35-GRIN/ENV (Ad35-GRIN and Ad35-ENV mixed in the same vial in equal proportions) or Ad35-GRIN was
administered intramuscularly at 0 and 6 months. Participants were randomized to receive either vaccine or placebo (10/4
per group, respectively) within one of four dosage groups: Ad35-GRIN/ENV 26109 (A), 261010 (B), 261011 (C), or Ad35-GRIN
161010 (D) viral particles.
Results: No vaccine-related serious adverse event was reported. Reactogenicity events reported were dose-dependent,
mostly mild or moderate, some severe in Group C volunteers, all transient and resolving spontaneously. IFN-c ELISPOT
responses to any vaccine antigen were detected in 50, 56, 70 and 90% after the first vaccination, and in 75, 100, 88 and 86%
of Groups A–D vaccine recipients after the second vaccination, respectively. The median spot forming cells (SFC) per 106
PBMC to any antigen was 78–139 across Groups A–C and 158–174 in Group D, after each of the vaccinations with a
maximum of 2991 SFC. Four to five HIV proteins were commonly recognized across all the groups and over multiple
timepoints. CD4+ and CD8+ T-cell responses were polyfunctional. Env antibodies were detected in all Group A–C vaccinees
and Gag antibodies in most vaccinees after the second immunization. Ad35 neutralizing titers remained low after the
second vaccination.
Conclusion/Significance: Ad35-GRIN/ENV reactogenicity was dose-related. HIV-specific cellular and humoral responses
were seen in the majority of volunteers immunized with Ad35-GRIN/ENV or Ad35-GRIN and increased after the second
vaccination. T-cell responses were broad and polyfunctional.
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Introduction
HIV/AIDS is a worldwide public health threat causing high
morbidity and mortality. At the end of 2010, the total number of
people living with HIV was estimated to be 34 million, up 17%
from 2001. This reflects the continued large number of new HIV
infections and a significant expansion of access to antiretroviral
therapy, which has helped reduce AIDS-related deaths, especially
in recent years [1]. Despite promising but still fragile successes in
prevention, care and treatment, the development of a safe and
efficacious preventive HIV vaccine, as part of a comprehensive
prevention program remains a global health priority, and the best
tool for long-term control of the HIV epidemic [2,3]. Although the
nature of the immune response needed to confer protection
against HIV infection is unknown, an effective immune response
will likely comprise antibodies and T cells that neutralize free virus
and/or recognize and eradicate cells infected with diverse strains
of HIV before an infection becomes irreversibly established [4].
Monomeric gp120 envelope subunits failed to induce neutral-
izing antibodies against circulating isolates and to confer
protection against HIV acquisition [5,6]. Generation of broadly
neutralizing antibodies is still a challenge [7,8] despite the recent
progress in isolating broad neutralizing monoclonal antibodies
against HIV [9,10,11,12,13,14,15,16]. Recent efforts have focused
on the development of HIV vaccines capable of inducing broad
cell-mediated responses that could reduce viral replication after
infection (‘‘T-cell vaccines’’) [17,18]. Although contradicted by
some studies [19], control of viral replication could slow the rate of
disease progression, as suggested by non-human primate (NHP)
challenge studies [20,21,22,23,24], and/or reduce transmission of
HIV from infected vaccine recipient to partner by reducing virus
load in the infected person [25].
Replication-incompetent viral vectors, including adenoviruses
and poxviruses are among current strategies for induction of cell-
mediated immune (CMI) responses in humans. The Step (HVTN
502/Merck 023) and Phambili (HVTN 503) vaccine trials were
the first human efficacy trials (phase IIb ‘test-of-concept’) to
explore whether a vector-based HIV-1 prophylactic vaccine aimed
at inducing CMI responses could prevent infection or reduce post-
infection viremia. The Merck vaccine was composed of replica-
tion-incompetent adenovirus serotype 5 (MRKAd5 HIV-1) vectors
expressing HIV-1 clade B non-envelope antigens. The Step study
enrolled, predominantly high-risk populations including men who
have sex with men (MSM) as well as heterosexual women in North
and South America and Australia, and heterosexual women and
men in the Caribbean [26,27]. The Phambili study enrolled
heterosexual men and women in South Africa [28]. HVTN 502/
Merck 023 was unexpectedly halted for futility in achieving the
study primary endpoints (follow-up continued for two years after
interim analysis) with an HIV incidence greater in vaccine than in
placebo recipients, mostly men having sex with men and subjects
with pre-existing Ad5-specific neutralizing antibody titers. The
biological basis for this observation remains unclear. Post-hoc
multivariate analysis further suggested that the greatest increased
risk was in men who had pre-existing Ad5-specific neutralizing
antibodies and who were uncircumcised [29,30]. Although the
MRKAd5 HIV-1 vaccine induced IFN-c ELISPOT responses,
and polyfunctional T cells by flow cytometry in the majority of
recipients, it did not result in a decreased viral load in HIV-
infected individuals [27]. Moreover, the immune response was
lower both in frequency and magnitude in individuals with pre-
existing Ad5 antibody titer .18 [27,31].
Recently, a phase IIb trial (RV144) of ALVAC-HIV and
AIDSVAXH gp120 B/E prime-boost enrolling Thai volunteers at
‘‘community risk’’ for HIV infection showed that, by modified
intent-to-treat analysis 3.5 years after initial vaccination, the
vaccine regimen was 31.2% efficacious in preventing HIV
infection. Six months after the last vaccination, HIV Env- and
Gag-specific IFN-c ELISPOT responses were detected in 19.7%
of vaccine recipients, Env-specific intracellular cytokine staining in
34%, and lymphoproliferative responses and binding antibodies to
Env in a majority of subjects. There was however, no effect on
early post-infection HIV-1 RNA viral load or CD4+ T-cell count
[32].
This paper describes a clinical study with an HIV vaccine based
on adenovirus serotype 35 (Ad35) that was designed to overcome
pre-existing humoral immunity, a hurdle faced by Ad5-based
vaccines. Ad35 is a human adenovirus serotype with low
seroprevalence. In addition, the prevalence and titers of Ad35
neutralizing antibodies are lower than those of Ad5 neutralizing
antibodies in Africa, Europe, North America and Asia [33,34]. In
adults, Ad35 seroprevalence was 10.6%–17.8% in South Africa,
14.8% in Kenya, 5.4% in Uganda, and 17.1% Thailand [35].
Ad35 belongs to subtype B of adenoviruses, which use highly
expressed CD46 as receptor, while Ad5 is a subtype C using the
coxsackie-adenovirus receptor (CAR) [36].
Recombinant Ad35-based vectors have been studied alone or in
prime-boost regimens with DNA or with another Ad vector, as
vaccines against HIV (NCT00479999: HVTN 072 and
NCT00801697: HVTN 077), tuberculosis (AERAS) [37] and
malaria (NCT01018459, NCT01366534, NCT00371189). The
vaccines are generally well tolerated and immunogenic. This
report describes a phase I dose-escalation, placebo-controlled,
randomized study of two Ad35 vectors, Ad35-GRIN containing
HIV-1 subtype A gag, reverse transcriptase, integrase and nef genes and
Ad35-ENV containing HIV-1 subtype A env gene tested in healthy
HIV-uninfected adults at low-risk of HIV acquisition.
Participants
Healthy HIV-uninfected male and female adults aged 18–50
years were recruited at the University of Rochester, NY, USA,
through information presented via the Internet, at community
organizations, hospitals, colleges, other institutions and/or adver-
tisements to the general public. Volunteers reported low-risk
behavior for HIV (i.e., no unprotected vaginal or anal sex with
known HIV-infected person; no sex in exchange for money or
drugs; no sexually transmitted infection within 6 months before
enrollment); and they were willing to undergo HIV testing and
receive results. Sexually active women participants agreed to use
effective contraceptive methods at least until 4 months after the
second vaccination and not to become pregnant. Only subjects
with negative baseline serum neutralizing antibodies against Ad35
were enrolled.
Interventions
Two recombinant replication-incompetent adenovirus serotype
35 (Ad35) vectors, Ad35-GRIN and Ad35-ENV, were generated
for this study. HIV-1 isolates used for the vector constructs were
obtained from the National Institute for Biological Standards and
Control repository, United Kingdom. Ad35-GRIN contains HIV-
1 subtype A gag (derived from HIV-1 isolate 01TZA173,
Tanzania), reverse transcriptase, integrase, and nef (derived from HIV-
1 isolate 00KE_MSA4070, Kenya) genes, designed as a fusion
product, and codon-optimized for human cell expression and
translation. Mutations were introduced into the reverse transcriptase
and integrase sequences to abrogate functional activity. Ad35-ENV
is expressing HIV-1 subtype A gp140 env gene (derived from HIV-
1 isolate 01TZA341, Tanzania). Ad35-GRIN/ENV consists of
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two vectors Ad35-GRIN and Ad35-ENV formulated in a 1:1
ratio. The Ad35 vectors were produced on an E1-complementing
human cell line (HER96). Vaccines and placebo were both
manufactured according to the principles of Good Manufacturing
Practices (GMP) by Transgene SA (Illkirch, France).
The Ad35-GRIN and Ad35-GRIN/ENV vaccines were pre-
pared in a formulation buffer composed of Tris 10 mM pH 8.5,
Sucrose 342.3 g/L, 1 mM MgCl2, Tween80 54 mg/L and
150 mM NaCl in water for injection and filled into single use
vials for intramuscular injection and presented as frozen sterile
solutions. The dosage of the vaccine is expressed as a total of virus
particles (vp). The formulation buffer was used as placebo. Each
vector, Ad35-GRIN and Ad35-ENV, was formulated at three
dosage levels: 16109 vp, 161010 vp and 1610611 vp for a final
dosage of Ad35-GRIN/ENV of 26109 vp (low dose, LD, Group
A), 261010 vp (mid dose, MD, Group B) and 261011 vp (high
dose, HD, Group C). Ad35-GRIN alone was administered at
161010 vp (Group D). Ad35-GRIN/ENV and Ad35-GRIN were
administered in a volume of 0.5 mL by needle injection in the
deltoid muscle at 0 and 6 months. Participants were randomized
within a dosage group to receive either vaccine or placebo in a
10:4 ratio. Each dosage group was enrolled sequentially in dose-
escalation manner. Group D was enrolled after all other groups
following an amendment to the original protocol. The demo-
graphic characteristics of the study population are described in
Table 1. The study screening was initiated in March 2009 and
completed in August 2011, volunteers were followed for 18 months
one year after the second immunization.
Objectives
The primary objective of the study was to evaluate the safety
and tolerability of a recombinant Ad35 vectors expressing multiple
HIV-1 proteins at different dosage levels, administered to healthy
HIV-uninfected adults. Shedding of Ad35-GRIN/ENV and
Ad35-GRIN after vaccination was also studied. The secondary
objective was to evaluate the humoral and cellular immunogenic-
ity of the vaccines at each dosage level and to explore a possible
Env immunodominance by comparing immune responses directed
against GRIN proteins between Groups B and D.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
This study was approved by the Western Institutional Review
Board (WIRB). The study was conducted in accordance with
International Conference on Harmonization - Good Clinical
Practice (ICH-GCP) and Good Clinical Laboratory Practice
(GCLP) [38]. All participants provided written informed consent.
Safety Monitoring
Study participants were monitored by interim medical history,
and by physical and laboratory assessments. Local (pain,
tenderness, erythema/skin discoloration, induration, vesicle/
ulceration, crust or scab) and systemic signs and symptoms (fever,
chills, headache, nausea, vomiting, malaise, myalgia, arthralgia)
Table 1. Demographic Characteristics of the Study Population.
Group A Group B Group C Group D
Ad35- GRIN/ENV Ad35-GRIN
Placebo 26109 vp 261010 vp 261011 vp 161010 vp Total
Number of Volunteers 16 10 10 10 10 56
Sex
Female 5 (31.3%) 3 (30.0%) 4 (40.0%) 7 (70.0%) 3 (30.0%) 22 (39.3%)
Male 11 (68.8%) 7 (70.0%) 6 (60.0%) 3 (30.0%) 7 (70.0%) 34 (60.7%)
Race
American Indian 1 (6.3%) 0 0 0 1 (10.0%) 2 (3.6%)
Asian 1 (6.3%) 0 1 (10.0%) 0 0 2 (3.6%)
Black 0 2 (20.0%) 0 3 (30.0%) 0 5 (8.9%)
White 14 (87.5%) 8 (80.0%) 9 (90.0%) 7 (70.0%) 9 (90.0%) 47 (83.9%)
Ethnicity
Hispanic or Latino 0 0 2 (20.0%) 0 2 (20.0%) 4 (7.1%)
Not Hispanic and Not Latino 16 (100.0%) 10 (100.0%) 8 (80.0%) 10 (100.0%) 8 (80.0%) 52 (92.9%)
Age (yrs)
Mean 31.0 24.2 24.6 29.2 24.0 27.1
Range 18–48 19–44 18–34 20–43 20–29 18–48
Vaccinations Received
First Vaccination 16 (100.0%) 10 (100.0%) 10 (100.0%) 10 (100.0%) 10 (100.0%) 56 (100.0%)
Second Vaccination 16 (100.0%) 9 (90.0%) 8 (80.0%) 9 (90.0%) 8 (80.0%) 50 (89.3%)
Follow-up Status
Completed 15 (93.8%) 8 (80.0%) 8 (80.0%) 9 (90.0%) 8 (80.0%) 48 (85.7%)
doi:10.1371/journal.pone.0041936.t001
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were solicited for 14 days after each vaccination. Subjects were
evaluated at the vaccination clinic on day 0 (pre- and 30 minutes
post-vaccination) and on days 3, 7 and 14 post each vaccination to
review their memory aids entries and record symptoms at that
time (Clinic Assessments). In addition, study subjects were given
14-day memory aid cards and instructed to record their maximal
symptoms experienced each day (Participant Assessments). Unso-
licited adverse events (AEs) were recorded throughout the study,
graded for severity (grade 1=mild, grade 2=moderate, grade
3= severe, grade 4=potentially life-threatening according to the
Division of AIDS Adult Adverse Event Grading Toxicity Tables,
version 1.0, December 2004) and classified by MedDRA (Medical
Dictionary for Regulatory Activities). The AEs were assessed for
relationship to study vaccines. There were five categories of
relatedness: definitely, probably, possibly, unlikely and not related.
Protocol deviations were monitored throughout the trial. The
Safety Review Board (SRB) authorized the dose escalation after
review of safety data of the lower dose group, based on a
compilation of blinded data from the first 9 volunteers enrolled.
Any severe and very severe events were provided to the SRB as an
update prior to proceeding with the next dosage level.
Ad35 Shedding
Ad35-GRIN/ENV and Ad35-GRIN shedding was studied by
collecting oro-pharyngeal swabs and urine specimens in a subset of
volunteers at days 0, 3, and 14 post 1st injection and prior to
booster injection at month 6. In addition, specimens for
adenovirus investigation were collected as clinically indicated
within the first 14 days post immunization for any reported
respiratory, genito-urinary, or diarrheal illness or conjunctivitis,
unless another cause was revealed by the diagnostic investigations.
Pairs of synthetic PCR primers specific for the ENV and GRIN
inserts were used to identify samples that might contain the
vaccine vector. Specimens were frozen on-site and batch tested
using a molecular diagnostic PCR assay by Esoterix Clinical Trial
Services (Cranford, NJ, USA).
Testing Algorithm for HIV Infection
Study participants were tested for the presence of antibodies to
HIV-1 and HIV-2 at the University of Washington Virology
Specialty Laboratory (Seattle, WA, USA) using the Abbott
HIVAB HIV-1/HIV-2 ELISA kit (Abbott Park, IL, USA) during
study screening (within 42 days of enrollment) and on the day of
enrollment prior to the first injection. Subsequently, at study weeks
4, 24 (prior to second injection), 32, and 52 serologic testing was
performed for all participants at a blinded laboratory using the
Bio-Rad Genetic Systems HIV 1/2 Plus O ELISA kit (Redmond,
WA, USA). If a post-enrollment ELISA was positive, additional
testing was done for the participant to distinguish vaccine-induced
responses from true infection, including a repeat Bio-Rad Genetic
Systems HIV 1/2 Plus O ELISA, a Bio-Rad Genetic Systems
HIV-1 Western Blot (Redmond, WA, USA) and an Abbott m2000
Real Time PCR HIV-1 RNA kit (Abbott Park, IL, USA).
Subsequently, at the final study visit, a full diagnostic panel of
serologic and virologic testing was conducted for all participants in
order to inform them of the likelihood of subsequent confusion
regarding the use of HIV serology for diagnostic purposes. This
panel included a Bio-Rad Genetic Systems HIV 1/2 Plus O EIA
(Redmond, WA, USA), Abbott Architect HIV Ab/Ag Combo
EIA (Abbott Park, IL, USA), Bio-Rad Genetic Systems HIV-1
Western Blot (Redmond, WA, USA), and Abbott m2000 Real
Time PCR HIV-1 RNA kit (Abbott Park, IL, USA).
Immunology Assays
All the primary immunogenicity assays (IFN-c ELISPOT, Ad35
neutralization and Env/Gag ELISA) are validated and run
according to GCLP guidelines, and the flow cytometry assay is
qualified. The IAVI Human Immunology Laboratory (HIL)
participates in EQA and/or IQA panels for IFN-c ELISPOT,
flow cytometry and PBMC preparation and passes the required
criteria [39,40,41].
Ad35 Neutralizing Antibody Assay
Presence of pre-existing antibody to Ad35 at screening was a
criterion for exclusion and was determined for each volunteer
prior to enrollment. Anti-Ad35 neutralization titers were measured
using heat-inactivated serum samples from 4 weeks after the first
vaccination and 2 weeks after the second vaccination in a
previously described, qualified cell-based assay [42]. Briefly,
A549 cells were seeded in a 96 well plate in the presence of
serially diluted serum. Following addition of luciferase-encoding
Ad35 reporter virus and incubation at 37uC for 24 hours,
luciferase activity in cell lysates was measured using a Victor3
multi-label plate reader (Perkin Elmer, Waltham, MA, USA) upon
addition of a substrate. Anti-Ad35 titers were calculated as the
serum dilution allowing a 90% reduction of luciferase activity in
infected cells (EC90). An EC90 cutoff of 16 was set where a
positive response was defined as EC90 $16 and a negative
response as EC90,16. Samples for the Ad35 neutralization assay
or the EnvA ELISA were run batched by groups and visits. Only
samples used to determine pre-existing immunity to the Ad35 were
run immediately upon receipt from the clinic to allow speedy
enrolment. For the Ad35 neutralization, each run includes
titration of a known positive control and negative control sera.
The titer from the positive control allows a comparison between
assays. Similarly, known positive and negative controls were run
on each ELISA plate.
HIV-specific Binding Antibodies
An ELISA assay was used to measure HIV specific Env-gp140
and Gag-p24 antibody responses at baseline and at indicated times
post-vaccination (Table 2). End-point titration of serum was
performed in 96-well medium binding plates (Greiner Bio-one,
Frickenhausen, Germany) coated with preparations of 2.5 mg/mL
purified recombinant subtype B Gag p24 (Aalto Bio Reagents
Ltd., Dublin, Ireland) or 5 mg/mL subtype A Env UG037
(Polymun Scientific Immunbiologische Forschung, Vienna, Aus-
tria). Titers were determined by sequential incubation of antigen
with serum followed by HRP-labeled anti-human IgG and TMB
(3, 59, 5, 59-tetra-methylbenzidine) substrate. After addition of
stop solution, the optical density (OD) at 450 nm was measured for
5-fold serially diluted samples starting at 1/100. The titer was
calculated as the most dilute serum concentration above the OD
cut off of 0.3 and 0.2 respectively for Env and Gag p24 and
reported as reciprocal dilution.
HIV-1 Neutralizing Antibodies
Sera were tested for neutralizing activity against HIV-1 two
weeks post-second vaccination at Monogram Biosciences, Inc.
(South San Francisco, CA, USA) as described elsewhere [43]. The
high-throughput assay utilizes a panel of recombinant viruses
pseudotyped with HIV envelope proteins covering a range of
neutralization sensitivity and geographic diversity as follows;
MGRM-A-001, MGRM-A-003, 94UG103 and 92RW020 (sub-
type A); JR-CSF, NL-4-3 and SF162 (subtype B); MGRM-C-026
(subtype C) and 94UG114 (subtype D). Neutralizing activity is
Adenovirus Subtype-35 Phase I HIV-1 Vaccine Trial
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expressed as the percent inhibition of viral replication (luciferase
activity) at each antibody dilution compared with an antibody-
negative control. Titers were calculated as the reciprocal of the
plasma dilution conferring 50% inhibition (IC50).
Peripheral Blood Mononuclear Cell Sample Preparation
and Peptide Stimuli
Peripheral blood mononuclear cells (PBMC) were isolated using
density gradient separation from heparinized whole blood, frozen
in a mixture of fetal bovine serum (Sigma-Aldrich, St Louis, MO,
USA) and DMSO (90:10 ratio) using a Kryo 560-16 rate
controlled freezer (Planer, Sunbury-On-Thames, UK). PBMC
were stored and shipped in vapor phase liquid nitrogen to the
IAVI HIL, Imperial College, London [44,45]. PBMC were
thawed, overnight rested and counted using a Vi-Cell XR counter
(Beckman Coulter, UK) for ELISPOT and flow cytometric
analyses using 6 HIV-1 15mer peptide pools, overlapping by 11
at 1.5 mg/mL per peptide, matching the vaccine inserts; one pool
each representing Gag, Pol/Int, RT, Nef and 2 pools representing
the Env sequence were used as stimuli.
IFN-c ELISPOT Assay
A validated IFN-c ELISPOT assay was the primary immuno-
genicity readout for this study and was conducted on participant
specimens obtained just prior to each vaccination, at weeks 2 and
4 after each vaccination and other timepoints as indicated in
Table 2. PBMC were plated in quadruplicate at 26105 viable
cells per well in the IFN-c ELISPOT assay with HIV-1 peptide
pools at 1.5 mg/mL, a peptide pool consisting of Cytomegalovirus
(CMV) pp65 peptides also at 1.5 mg/mL, PHA at 10 mg/mL and a
mock stimulus (DMSO/medium) as previously described [44,45].
Spot forming cells (SFC) were counted using an automated AID
ELISPOT reader (Autoimmun Diagnostika, Strassberg, Ger-
many). The number of SFC/106 PBMC had to satisfy the
following criteria: 1) Average number of background-subtracted
spots in a single pool .38 SFC; 2) For each pool, if the number of
replicates is greater than one, the coefficient of variation (Standard
Deviation/Mean) between replicates should be ,70%; 3) Mean
count must be .4 times mean background; 4) Mean background
must be #50 SFC/106 PBMC. Assays with mean background
.55 SFC/106 PBMC were considered failures and excluded from
further analysis if a repeat test confirmed this. In cases where a
response to a peptide pool was found to be positive at baseline,
subsequent responses to this pool were not included in the
determination of response rate.
The IAVI HIL has a validated ELISPOT assay and samples
are run in batches in approximate chronological order of receipt.
To ensure stability of the assay over time, a replicate reference
quality control (QC) PBMC is run on each assay day, and an
internal QC CMV antigen and PHA for each volunteer
immunogenicity study visit is run. The coefficient of variation
(CV) has remained stable over time with a CV of ,30%. Each
volunteer’s CMV, PHA and mock responses have remained
stable over time with low CV.
Polychromatic Flow Cytometry
The antigen-specific phenotype and cytokine secretion profiles
were assessed at baseline and 2 weeks post-second vaccination in
Groups B-D using a qualified polychromatic flow cytometry (PFC)
panel. PBMC were co-incubated with HIV-1 peptide pools, 1 mg/
ml SEB (Sigma-Aldrich, St. Louis, MO, USA) or mock stimuli,
CD107a PECy5, BD Golgistop (Becton Dickinson, San Jose, CA,
USA) and Brefeldin A (Sigma-Aldrich, Poole Dorset, UK) for 6
hours at 37uC. Cells were stained for viability with 100 mL LIVE/
DEADH Fixable Violet Dead Cell Stain Kit (Invitrogen, Eugene,
OR, USA), and then surface stained by anti-CD4 QD605, anti-
CD8 pacific orange, anti-CD19 pacific blue (Invitrogen, Paisley,
UK), anti-CD27 APC-H7, anti-CD14 pacific blue, anti-CD57
FITC, anti-B7 integrin PE (Becton Dickinson, San Jose, CA), and
anti-CD45RO ECD (Beckman Coulter, High Wycombe, UK).
Finally cells were stained intracellularly with anti-CD3 QD655
(Invitrogen, Paisley, UK), anti-IFN-c PE Cy7, anti-TNF-a A700
and anti-IL-2 APC (Becton Dickinson, San Jose, CA, USA). At
least 750,000 events were acquired on a custom-built BD LSR II
cytometer. Data were analyzed and presented using FlowJo
(version 8.8 Treestar), PESTLE and SPICE (version 5.1, http://
exon.niaid/nih.gov/SPICE/) software [46]. The percentage of
cytokine-producing cells after antigen stimulation was considered
positive if it fulfilled the following three criteria: 1) the response
was at least two times greater than the percentage of cytokine-
producing cells in the mock pool at the same post-vaccination time
point, 2) the response to the same antigen was negative at pre-
vaccination baseline, and 3) for each cytokine the response was
superior or equal to the 97.5 percentile of all baseline responses to
that peptide (Groups B–D). Data were not included for analysis if
cell viability was less than 80% at the time of assay set-up or if
fewer than 50,000 events were present in the CD3+ gate or less
than 10,000 events in either CD4+ or CD8+ gates. In order to be
included in the sample analysis, all samples had to test positive for
cytokine production when stimulated by staphylococcal entero-
toxin B (SEB, Sigma-Aldrich, St Louis, MO, USA).
Table 2. Number of Volunteers Enrolled, Vaccination Schedule, Sample Collection and Assessment time points.
Groupa Vaccines/Dosage Preb W0 W2 W4 W24 W25 W26 W28 W32 W38 W52, 64 & 72
A (10/4) Ad35-GRIN/ENV 26109 vp c d,e,f d c,d,e d,e d c,d,e,f d,e d d,e d,e
B (10/4) Ad35-GRIN/ENV 261010 vp c d,e,f d c,d,e d,e d c,d,e,f d,e d d,e d,e
C (10/4) Ad35-GRIN/ENV 261011 vp c d,e,f d c,d,e d,e d c,d,e,f d,e d d,e d,e
D (10/4) Ad35-GRIN 161010 vp c d,e,f d c,d,e d,e d c,d,e,f d,e d d,e d,e
W = week, W0 and W24 are vaccination visits.
a(V/P) Number of Vaccine recipients/number of Placebo recipients per group.
bScreen window up to 65 days prior to enrollment for anti-Ad35 antibodies.
cSerum neutralizing antibodies against Ad35.
dVaccine-induced HIV-1 specific IFN-c ELISPOT responses.
eVaccine-induced HIV-1 specific humoral immune responses (Env and p24 Gag ELISA).
fPolychromatic Flow Cytometry.
doi:10.1371/journal.pone.0041936.t002
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For the PFC assay, batches of baseline and matched post-
vaccine samples are thawed on the same day and data accrual is
performed within 18 hours. Daily QC of the LSRII is performed
as described previously [47]. Daily voltages are tracked over time
to ensure consistency between individual runs. Additionally, the
responses to CMV antigen of a control PBMC sample are pre-
determined by testing over 20 individual timepoints. An aliquot of
this control is then run in parallel to clinical trial samples to ensure
that responses do not vary more than 2 SD during the study.
Sample Size and Pause Rules
Safety interim analyses. Blinded summary tables and
listings of adverse events, including solicited reactogenicity events,
were presented to an independent Safety Review Board (SRB).
Approval for dose-escalation was made by the SRB after review of
unblinded two-week safety data after first injection from the first
nine participants in Groups A and B.
Randomization and blinding. This study was a double-
blind, randomized, placebo-controlled, dose-escalation Phase I
clinical trial. The randomization schedule was prepared by
statisticians at the Data Coordinating Center, EMMES
Corporation. The randomization list was sent to the site
pharmacist of record for dispensing of vaccine and placebo in a
double-blind fashion. Study site staff, volunteers, and labora-
tories remained blinded with respect to the allocation of
placebo or vaccine.
Statistical methods. The planned sample size of 56
volunteers (40 vaccine/16 placebo) was considered to be
appropriate for an exploratory clinical trial for evaluating
safety while also providing relevant information on vaccine-
induced immune responses. If none of the 10 volunteers in any
active vaccine group experienced a serious adverse event
related to the Investigational Product, then the upper 95%
confidence limit for the rate of these adverse events in the
population was 30.8% (by the Clopper-Pearson method). Due
to the small sample size, the trial had limited power to rule out
smaller differences in safety and immunogenicity results. For
comparison of active vaccine (N = 40) versus placebo (N = 16),
there was 80% power to detect a statistically significant
(p,0.05) difference of 28.5% and 32.7% if the event rate in
the placebo group was 1% or 5%, respectively (Fisher’s exact
1-tailed test). Fisher’s exact test (for categorical variables) and
Kruskal-Wallis Test (for continuous variables) were used to
compare the balance and/or values of baseline characteristics
between the study groups. All safety and immunogenicity
comparisons were made using Fisher’s exact, 2-tailed tests of
the proportions of volunteers with an endpoint, unless
otherwise stated. The safety comparisons were based on the
maximum severity per volunteer. All tests are 2-tailed;
statistical significance is defined as a p,0.05. However, when
pairwise comparisons among the study groups were conducted,
p,0.01 was considered to be statistically significant. Analyses
were performed using SAS version 9.2, (SAS, Cary, NC, USA).
Results
Participant Flow and Recruitment
A total of 176 adults between 18-50 years of age were screened
at the study site in order to enroll 56 participants into the protocol
(Figure 1). The most common reasons for not qualifying for the
study were 1) did not meet the eligibility requirements due to
medical and/or behavioral reasons (n = 64, 36.4%), 2) declined to
participate after receiving a full explanation of study procedures
(n = 22, 12.5%) and 3) presence of pre-existing anti-Ad35
neutralizing antibodies at screening (n= 8, 4.5%). Six enrolled
study participants did not receive the second injection at 6 months
(however two of them completed the study follow-up; 1 due to
pregnancy after the 12-week study visit and the other due to
relocation that made attendance at the frequent early post-
vaccination follow-up visits impossible). Eight subjects did not
complete study visits, five for personal reasons and three for loss to
follow-up (Figure 1). Table 1 describes the demographic
characteristics of the enrolled volunteers.
Protocol Deviations
There were 123 minor protocol deviations in this study, mostly
involving isolated inability to obtain complete collections of
biological specimens (i.e., shortage of blood volume due to poor
venous access or lack of urine specimen due to subjects’ inability to
void), or minor deviations involving protocol-specified study visit
windows or schedule compliance. In addition, routine oro-
pharyngeal specimens for Ad35 viral shedding were not collected
from the first 9 and first 5 participants in study Groups B and C,
respectively, but adequate routine specimens were collected from
the first 9 subjects in study Groups A and D and from all study
subjects who presented with respiratory tract symptoms. The
interpretation of the data presented here is not affected by the
protocol deviations.
Vaccine Safety
Solicited events. The time course by study group for
maximal symptoms localized to the injection site and for maximal
systemic symptoms after each injection is shown in Figure 2,
panels A and B, and panels C and D, respectively.
Local Reactogenicity. The majority of local vaccination-site
reactions graded as mild or moderate after the first and second
injections; the overall frequency of any local reaction was 80% in
Group A, 100% in Groups B, C and D, and 81.3% among the
placebo recipients (Figure 2A, Table S1). Severe reactions were
observed in one subject from Group A post-second vaccination
(pain and tenderness), one subject from Group B post-second
vaccination (pain), and three subjects in Group C: two post-first
vaccination (pain and tenderness in both) and two subjects (one of
them with reactogenicity post-first vaccination) post-second
vaccination (tenderness). These reactions were self-limited and
resolved within 1–3 days. The occurrence of moderate or severe
reactions did not seem to increase after the second vaccination in
any dose group. Erythema at the injection site was unusual in all
groups. Induration (present, less than grade 1) was observed in one
volunteer post-second vaccination in Group A. Formation of a
scab (present, less than grade 1) was observed in one volunteer
post-second vaccination in Group B and in one volunteer post-first
vaccination in Group D, each resolving within 1–3 days.
Systemic reactogenicity. Overall, the frequency of any
systemic reaction was 60% in Group A, 70% in Group B, 100%
in Group C, 80% in Group D, and 68.9% in Placebo. These
reactions were mild or moderate among participants in Groups A,
B and D, except in one volunteer in Group A who had severe
myalgia, arthralgia and malaise post-second vaccination In
addition, one placebo recipient reported a severe headache after
the first vaccination. Of note, 5 subjects (50%) in Group C, who
received the highest dose, had severe systemic reactions that
resulted in cancellation of scheduled activities (Figure 2B, Table
S2). As assessed by the volunteer and validated by the clinic, of
those who had severe symptoms in Group C, one had symptoms
that lasted an unusually long time: severe malaise, chills, myalgia
and headache for 5 days, with severe injection-site pain and
tenderness for 3 days, all beginning on Day 0, and fully resolving
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at Day 8. The other four subjects experienced more brief
symptoms. One had severe myalgia on Day 1, which resolved
the next day; one volunteer had severe chills, malaise and fever
(39.9uC) on Day 1 only. Another volunteer had severe chills and
malaise with moderate fever (38.9uC) at Day 1. The other subject
had severe headache and pain for one day and severe tenderness
for 2 days. Among these latter four subjects, all reactions began
about 12 hours after vaccination, diminished in severity over the
ensuing 12 hours, and resolved or became mild within 2–3 days.
The participant who experienced the prolonged ‘flu-like illness’
was tested at day 3 after onset for influenza as pandemic H1N1
influenza was known to be circulating in the community at the
time, but oro-pharyngeal culture and PCR were negative.
Evidence of intercurrent influenza illness was also sought for all
other study participants who experienced moderate to severe
systemic symptoms after vaccination, but all results were negative.
Of note, all subjects in Group C (except for the woman who
became pregnant) agreed to receive their second vaccination at 6
months, which was much better tolerated with mostly mild and
moderate reactions (Tables S1 and S2).
Ad35 shedding. No Ad35 shedding, as assessed by recombi-
nant vector-specific PCR, was detected in oro-pharyngeal swabs
and urine specimens obtained routinely from any study group (328
samples: 130, 4, 46 and 148 in Groups A, B, C and D,
Figure 1. CONSORT Flow Diagram. Number of individuals assessed for eligibility, enrolled and randomized to study vaccine(s) and respective
placebo, followed-up and analyzed.
doi:10.1371/journal.pone.0041936.g001
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Figure 2. Time Course of Local and Systemic Reactions Post First (Vac1) and Post Second (Vac2) Vaccination per Maximum Severity
Assessment for Placebo, Group A (26109 vp), Group B (261010 vp), Group C (261011 vp) and Group D (161010 vp). The Y-axis of
Figure 2 represents the number of volunteers experiencing reactogenicity events (panel A for local reactions and panel B for systemic reactions post
first and second vaccinations, upper and lower rows respectively) for each group, while the X-axis represents the days of occurrence of the events,
Day 0 being the day of vaccination. Volunteers did a self-assessment of reactogenicity with a memory card on Day 0 (evening of vaccination) and
daily through Day 13, reviewed by the investigator at Days 3, 7 and 14. The figure shows the maximum severity assessment grade recorded as per the
volunteer’s and clinic’s assessments combined. The severity grade of the reactogenicity events is indicated by color codes (mild: yellow; moderate:
orange; severe: red).
doi:10.1371/journal.pone.0041936.g002
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respectively). In addition, no oro-pharyngeal swab samples tested
from volunteers presenting with upper or lower respiratory
symptoms (99 samples: 18, 10, 43 and 78 in Groups A, B, C
and D, respectively) were positive for Ad35.
Unsolicited adverse events. A total of 171 non-serious
adverse events (AEs) were reported by study participants during
the course of the study (61 in Placebo, 25 in Group A, 27 in Group
B, 30 in Group C and 28 in Group D). The frequency was not
dose-related. One hundred and eight events were graded as mild
(grade 1) in severity and 61 were graded as moderate (grade 2).
Only 2 events were assessed as severe (grade 3): deep vein
thrombosis and anxiety disorder; both were considered unrelated
to the vaccine. Ten events were considered as possibly related to
vaccine (diarrhea, injection site hemorrhage, 2 influenza-like
illness, upper respiratory tract infection, pharyngo-laryngeal pain,
pharyngitis, naso-pharyngitis, and 2 nasal congestion), one as
probably related (injection site anesthesia) and one definitely
related (injection site swelling). All other events were considered
unrelated or unlikely to be related to vaccination.
Laboratory abnormalities. Moderate or greater abnormal
clinical laboratory values were observed in five volunteers:
elevated aspartate aminotransferase of moderate grade in two
subjects (one in Group A prior to second vaccination and one in
Group B 98 days post-second vaccination), and moderate grade
low hemoglobin in two female participants. One subject from
Group D had severe elevation of alanine aminotransferase 24
weeks after the first injection, just prior to the second vaccination.
All of these abnormalities were judged to be unrelated to the study
vaccinations and returned to values within the normal range
during study follow-up.
Serious adverse event. Two Serious Adverse Events (SAE)
were reported during the study; both were unrelated to
vaccination. One was a subject who was hospitalized for accidental
trauma of the knee. The second SAE was a subject with
cholelithiasis which was treated by cholithectomy.
Social impact. One participant experienced difficulties in
enlisting into the Armed Services due to vaccine-induced HIV
seropositivity (VISP). After intervention of the research team, and
of a representative from the US Military HIV Research Program
for additional HIV testing, the participant was confirmed HIV-
uninfected and able to join the Armed Services approximately six
months later. Another participant was found to be seropositive for
HIV as a part of routine health care visit having failed to mention
his/her participation in the study. This person was also found to
have VISP rather than true infection when the study team was
consulted. Lastly a third participant attempted to donate blood
and was denied due to his/her HIV status. Through additional
testing this individual had VISP, but is no longer able to donate
blood due to the current Red Cross guidelines.
Pregnancies. One woman in the high-dose Ad35-GRIN/
ENV group who utilized an intrauterine device for contraception
was found to be pregnant 5 months after the first vaccination. She
did not receive her second study vaccination but continued with
follow-up and completed the study on schedule. She delivered a
healthy full-term baby.
Incident HIV infections. No incident HIV infection was
detected among enrolled study participants throughout the study.
Vaccine Immunogenicity
IFN-c ELISPOT response. IFN-c ELISPOT was the
primary assay assessing cellular responses among groups in this
study and was performed longitudinally as indicated in Table 2,
responses at weeks 25, 32 and 52 are not reported here. The
median percent viability of 599 PBMC samples after processing
was 97.8% (range 82–100%); after storage, shipment and thawing
of PBMC for the ELISPOT assay, the median percent viability of
565 PBMC samples up to 1 year after vaccination was 97.7%
(range 77.7–99.7%). Eleven of 600 (,2%) ELISPOT samples
tested failed to meet laboratory quality criteria.
Frequency of positive responses. The frequency of partic-
ipants by study group with positive IFN-c ELISPOT responses 2
and 4 weeks after each vaccination, as well as 14 and 48 weeks
after the second vaccination is shown in Table 3. IFN-c ELISPOT
responses to any vaccine antigen were detected in 50%, 50% and
78% at 2 weeks and in 50%, 56% and 70% of vaccine recipients at
4 weeks post-first vaccination, in groups A, B and C respectively.
Responses to any vaccine antigen in groups A–C were also
detected in 86%, 100% and 89% of vaccine recipients at 2 weeks
post-second vaccination and in 75%, 100% and 88% of vaccine
recipients at 4 weeks post-second vaccination, respectively.
Responses to Ad35-GRIN alone (Group D) were present in 89%
and 90% of participants at 2 and 4 weeks after the first vaccination
and in 86% of participants 2 and 4 weeks after the second
vaccination. At 48 weeks after the second vaccination, IFN-c
ELISPOT responses to any vaccine antigen in Groups A–D were
detected in 57%, 100%, 63% and 88% of vaccine recipients,
respectively.
No assays were positive among vaccine recipients prior to the
first vaccination. There was one placebo recipient with a low ENV
response at baseline, which persisted at all post-vaccination
timepoints. Conversely, considering all timepoints examined with
this assay during the study, only 2 of 40 vaccine recipients failed to
have a positive response during at least one visit. Overall IFN-c
ELISPOT response rate in vaccine recipients (90%) was signifi-
cantly higher than the rate in placebo recipients (0%) at 2 weeks
post second vaccination (p,0.0001).
Repeatedly positive IFN-c ELISPOT responses over time
among individuals in all vaccine groups were commonly observed;
the median number of positive assays per participant was 7.5, 9, 9
and 10 over 8–10 available visits for Groups A–D, respectively
(data not shown). Breadth of the response as defined by the
median number of positive responses among vaccinees to any of
the six peptide pools for Groups A–C was 3.5, 5 and 5,
respectively. For Group D, where only 4 peptide pools were
tested, the median number of positive responses among vaccinees
was 4. Figure S1 shows the frequency and distribution of peptide
pool responses over time in each group, providing an additional
perspective of the breadth of the response to the vaccine regimens.
In this case, five pools are included in this analysis; Gag, Pol/Int,
RT, Nef and Env pools. Responses of up to 4 pools were
commonly observed across all the groups and over multiple
timepoints indicating that good breadth was seen early and
persisted over time.
Magnitude of Positive Responses
The median magnitude (log-scale) of positive IFN-c ELISPOT
responses across all peptide pools by vaccination group is shown
in Figure 3. Each group that received Ad35-GRIN/ENV had a
median response magnitude to any antigen ranging from 84 to
114 SFC/106 PBMC, with some significant differences between
the three dosage levels. The median SFC/106 PBMC to any
antigen was 78–139 across Groups A–C and 158–174 in Group
D after each of the vaccinations (Table S3). Responses were seen
across all proteins with ranges from ,100 SFC to ,3000 SFC/
106 PBMC. Overall, post-vaccination, there was a significant
difference in the response among Ad35-GRIN recipients (Group
D) and Ad35-GRIN/ENV recipients (in Groups B and C) for
Gag, Pol/Int and Nef pools (Figure 4). The Gag response in
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Group D was significantly higher than in Group B (p = 0.001)
and Group C (p = 0.007). In addition, Pol/Int response in Group
D was significantly higher than in Group B (p = 0.0001), and Nef
response in Group D was significantly higher than in Group B
(p = 0.001), and Group C (p= 0.001). Responses of high
magnitude to Gag, RT and Pol/Int were seen in several
individuals from multiple groups at the peak of the response (2
or 4 weeks post-second vaccine), but the magnitude of IFN-c
ELISPOT responses to Nef and Env were generally lower
(Figure 4 and Table S3). There did not appear to be any
pattern across the groups with regard to the frequency of
responses to individual antigens, indicating no particular im-
munodominance. However, in Group D, the balance of responses
to the four antigens was similar at 2 weeks post-second vaccine;
86% response rate to Gag, 71% for RT and Pol/Int and 57% to
Nef. Group D also had the highest Nef response rate compared
with Groups A–C.
Polychromatic Flow Cytometry
Polychromatic flow cytometry (PFC) assays to characterize the
responding T-cell phenotype and assess polyfunctionality were
performed on cryopreserved PBMCs at study baseline and 2 weeks
after the second vaccination for Groups B–D. For PFC assays, the
mean cell recovery for vials of 107 PBMC/mL was 8.26106 (4.9–
16.5) with a mean viability of 94.7% (82.3–99.3%). All samples
tested positive for cytokine production when stimulated by SEB.
The gating strategy is shown in Figure S2. HIV-1 specific CD8+
T-cell responses were more commonly observed than CD4+ T-cell
responses, and displayed polyfunctional phenotype with IFN-c,
TNF-a production and CD107 expression dominating the
response and with a low frequency of IL-2 production (Tables 4
and 5). No obvious dose response effect on magnitude was
observed but, CD8+ responses were greater in Group D than in
Groups B or C. The magnitude of both CD4+ and CD8+ cytokine
positive T cells were greater post-vaccination than at baseline or in
the placebo group (Tables 4 and 5). The magnitude of the
responses detected by PFC and IFN-c ELISPOT were compara-
ble; individuals with high magnitude responses to Gag, RT and
Pol/Int in the IFN-c ELISPOT also had high PFC responses. For
example, there was one individual in Group D with a magnitude
of 2.18% Nef-specific CD8+ T cells who also had an IFN-c
ELISPOT response of 1060 SFC/106 at the same timepoint. The
magnitude of responses to Nef and Env were generally lower in
both the PFC and IFN-c ELISPOT. CD4+ T-cell response rates
to the individual peptide pools were low and sporadic (only 1 or 2
responders to one pool in each group). There were no Env-specific
CD8+ T-cell responses observed in Groups B or C, but CD8+ T-
cell responses were seen to Gag and RT in Groups B–D (Table
S4). The numbers of samples available in each group precluded
statistical analysis of response rate between groups and protein
inserts.
HIV-specific Antibody Responses
HIV-specific IgG antibody responses to a subtype A UG037
gp140 protein were measured at baseline, 4 and 24 weeks after the
first vaccination and 2, 4, 14, 28, 40 and 48 weeks after the second
vaccination. One of 12 subjects (8%) who received placebo had a
positive response at all time points including baseline, while none
of the subjects in Groups A–C (0/9, 0/8, 0/9, respectively) had
positive responses at baseline. The majority (80–100%) of
vaccinated volunteers in Groups A–C had a positive IgG gp140
ELISA at 4 weeks post-first immunization while all had positive
responses at two weeks post-second immunization (Figure 5,
Table S5) as defined by a titer greater than or equal to 100 at the
assay cut-off. The positive response rate at both 4 weeks post-first
vaccination and 2 weeks post-second vaccination was significantly
higher in the vaccine groups compared to placebo (p,0.0001).
Geometric mean titers (and range) were calculated among those
responders with quantifiable titers. There was a significant rise in
Env antibody titer post-second vaccination in the vaccine groups
(signed rank test; p,0.0001), based on the log titer difference
between baseline and 2 weeks post-second vaccine. Antibody titers
fell significantly from 4 weeks post first vaccination to prior to the
second vaccination (p= 0.0002) and going from 2 weeks to 14
weeks after the second vaccination (p,0.0001). Antibody titers
peaked 2 weeks after the second vaccination and slowly decreased
over time. There was no significant difference in the distribution of
titers (p = 0.07) at 2 weeks post-second vaccination among the
vaccine groups.
Subtype B Gag p24-specific IgG antibody responses were also
measured at baseline, 2, 4 and 24 weeks after the first vaccination
and 2 and 14 weeks after the second vaccination. Such antibodies
were detected in none of the vaccinated individuals at 4 weeks
post-first immunization and in 0%, 38%, 89% and 71%
Table 3. Overall IFN-c ELISPOT response rate for the 6 peptide pools in vaccine groups at selected time points with cryopreserved
PBMC.
Ad35-GRIN/ENV Ad35- GRIN/ENV Ad35-GRIN/ENV Ad35-GRIN
Time Point 26109 vp 261010 vp 261011 vp 161010 vp
Overalla, b, c 10/10 (100%) 9/10 (90%) 10/10 (100%) 9/10 (90%)
Pre-Vaccination 0/9 0/10 0/10 0/10
2 weeks Post 1st vaccination 4/8 (50%) 5/10 (50%) 7/9 (78%) 8/9 (89%)
4 weeks Post 1st vaccination 5/10 (50%) 5/9 (56%) 7/10 (70%) 9/10 (90%)
2 weeks Post 2nd vaccination 6/7 (86%) 8/8 (100%) 8/9 (89%) 6/7 (86%)
4 weeks Post 2nd vaccination 6/8 (75%) 7/7 (100%) 7/8 (88%) 6/7 (86%)
14 weeks Post 2nd vaccination 5/9 (56%) 8/8 (100%) 7/9 (78%) 7/8 (88%)
48 weeks Post 2nd vaccination 4/7 (57%) 8/8 (100%) 5/8 (63%) 7/8 (88%)
aNot all samples from all time points were tested due to assay failure, missed visits or volunteer withdrawal.
bA volunteer is defined as a responder if they score positive to any pool.
cOne placebo recipient had a positive ENV ELISPOT at baseline; otherwise all tests for placebo recipients were negative (data not shown in table).
doi:10.1371/journal.pone.0041936.t003
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Figure 3. IFN-c ELISPOT Response Magnitude (SFC/106 PBMC) and Responder Rate (%) to Any HIV Antigen by Time Post
Vaccination (X-axis) and Dose Groups. Gray dots: response below the cut-off to any of the 6 peptide pools; red dots: response above the cut-off
to any of the 6 peptide pools. For the vaccine groups, the overlaid box plot summarizes the positive responses (i.e., the median, 1st and 3rd quartiles
and minimum/maximum). For the baseline (BL) and placebo (Pbo) group, the box plot summarizes the negative responses and the red dot displays
the single positive response at baseline.
doi:10.1371/journal.pone.0041936.g003
Figure 4. IFN-c ELISPOT Response Magnitude by peptide pool. The panels show individual background-subtracted IFN-c ELISPOT counts to
each antigen at 2 weeks post the second vaccination for each peptide pool and by each vaccine group. The horizontal lines indicate median values
for each group. SFC = spot forming cells.
doi:10.1371/journal.pone.0041936.g004
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respectively of vaccine recipients from Groups A, B, C and D
at 2 weeks after the second vaccination as defined by a titer
greater than or equal to 100 at the assay cut-off. (Figure 5,
Table S5). Geometric mean titers (and range) were calculated
among those responders with quantifiable titers. The positive
response rate at 2 weeks post-second vaccine was significantly
higher in Groups B, C and D compared to Group A and
placebo (p,0.0001). There was a significant rise in antibody
titer post-second vaccination in Groups B, C and D (signed
rank test; p = 0.001), based on the log titer difference between
2 weeks post first vaccination and 4 weeks post-second
vaccination. In Groups B, C and D, the antibody titer did
not significantly change going from 2 to 14 weeks post-second
vaccination (p = 0.63). There was no significant difference in
the distribution of titers (p = 0.08) at 2 weeks post-second
vaccination between Groups B, C and D.
Table 4. Polychromatic flow cytometry of Env-specific T cells.
ENV-specific CD8+ T cells ENV-specific CD4+ T cells
IFN-c CD107a TNF-a IL-2 IFN-c CD107a TNF-a IL-2
aBaseline cMedian 0.023 0.030 0.012 0.027 0.013 0.006 0.012 0.034
cRange 0–0.224 0–0.100 0–0.099 0–0.115 0–0.150 0–0.028 0–0.358 0–0.313
Positive/tested (%) 2/25 (8.0%) 0/25 (0%) 1/25 (4.0%) 0/25 (0.0%) 3/25 (12.0%) 0/25 (0%) 1/25 (4.0%) 1/25 (4.0%)
bPlacebo cMedian 0.005 0.028 0.009 0.012 0.023 0.003 0.013 0.026
cRange 0–0.121 0.008–0.088 0–0.057 0.002–0.127 0–0.099 0.002–0.034 0.003–0.033 0.015–0.125
Positive/tested (%) 0/7 (0%) 0/7 (0%) 0/7 (0%) 0/7 (0.0%) 1/7 (14.3%) 1/7 (14.3%) 0/7 (0%) 0/7 (0.0%)
bGroup B cMedian 0.065 0.041 0.041 0.030 0.042 0.008 0.072 0.072
cRange 0–0.176 0–0.156 0.010–0.197 0.014–0.079 0.017–0.095 0–0.034 0.029–0.157 0.022–0.149
Positive/tested (%) 1/8 (12.5%) 1/8 (12.5%) 1/8 (12.5%) 0/8 (0.0%) 1/8 (12.5%) 0/8 (0%) 2/8 (25.0%) 3/8 (37.5%)
bGroup C cMedian 0.050 0.035 0.048 0.047 0.061 0.010 0.047 0.052
cRange 0.026–0.157 0.008–0.273 0.025–0.165 0.017–0.093 0.020–0.264 0–0.032 0.015–0.780 0.032–0.205
Positive/tested (%) 1/9 (11.1%) 1/9 (11.1%) 1/9 (11.1%) 0/9 (0.0%) 1/9 (11.1%) 1/9 (11.1%) 1/9 (11.1%) 1/9 (11.1%)
aAll samples at baseline,
bSamples at 2 weeks post second vaccination,
cFrequency of positive cells.
doi:10.1371/journal.pone.0041936.t004
Table 5. Polychromatic flow cytometry of GRIN-specific T cells.
GRIN-specific CD8+ T cells GRIN-specific CD4+ T cells
IFN-c CD107a TNF-a IL-2 IFN-c CD107a TNF-a IL-2
Baseline cMedian 0.087 0.083 0.073 0.077 0.043 0.022 0.064 0.086
cRange 0–0.304 0–0.541 0–0.543 0.010–0.640 0–0.265 0–0.091 0.009–0.360 0.027–0.590
Positive/tested (%) 2/36 (5.6%) 1/36 (2.8%) 1/36 (2.8%) 0/36 (0.0%) 0/36 (0.0%) 2/36 (5.6%) 0/36 (0.0%) 0/36 (0.0%)
Placebo cMedian 0.077 0.076 0.103 0.165 0.040 0.025 0.082 0.191
cRange 0.010–0.380 0.024–0.208 0–0.860 0.015–1.330 0–0.296 0.005–0.087 0.034–0.780 0.042–1.220
Positive/tested (%) 0/11 (0%) 0/11 (0%) 0/11 (0%) 0/11 (0%) 0/11 (0.0%) 1/11 (9.1%) 0/11 (0.0%) 0/11 (0.0%)
Group B cMedian 0.247 0.277 0.158 0.156 0.127 0.018 0.111 0.160
cRange 0.068–2.142 0.079–1.357 0.079–1.911 0.065–0.671 0.052–0.256 0–0.044 0.029–0.203 0.085–0.245
Positive/tested (%) 4/8 (50.0%) 4/8 (50.0%) 3/8 (37.5%) 2/8 (25.0%) 1/8 (12.5%) 0/8 (0.0%) 3/8 (37.5%) 3/8 (37.5%)
Group C cMedian 0.280 0.109 0.160 0.131 0.105 0.019 0.092 0.128
cRange 0.060–2.710 0.059–2.670 0.030–2.836 0.034–0.331 0.007–0.491 0.004–0.062 0.026–0.324 0.042–0.219
Positive/tested (%) 4/9 (44.4%) 3/9 (33.3%) 3/9 (33.3%) 4/9 (44.4%) 1/9 (11.1%) 1/9 (11.1%) 1/9 (11.1%) 0/9 (0.0%)
Group D cMedian 0.564 0.341 0.408 0.236 0.129 0.012 0.208 0.191
cRange 0.027–3.361 0.022–1.370 0.051–3.019 0.121–0.529 0.048–0.318 (0.010–0.033) 0.127–0.372 0.166–0.370
Positive/tested (%) 6/7 (85.7%) 6/7 (85.7%) 6/7 (85.7%) 3/7 (42.9%) 3/7 (42.9%) 0/7 (0%) 5/7 (71.4%) 1/7 (14.3%)
aAll samples at baseline,
bSamples at 2 weeks post second vaccination,
cFrequency of positive cells.
doi:10.1371/journal.pone.0041936.t005
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HIV Neutralizing Antibody Response
None of the samples had neutralizing titers above the cut-off of
the assay against any of the 9 viruses tested (data not shown).
Ad35-specific Neutralizing Antibody Response
Samples were tested for the presence of Ad35-specific neutral-
izing antibodies at baseline, 4 weeks post-first vaccination and 2
weeks post-second vaccination. Responses were seen in only 10–
30% of participants in Groups A–D after the first vaccination and
were generally of low titer; the median titer among those that
scored positive in the assay at that time was 56, 171, 32 and 40 in
the four groups, respectively. (Table S5, Figure S3). However,
Ad35 neutralization was observed more frequently after the
second vaccination, with a dose-dependent trend towards an
increased response rate, with 33%, 38%, 89% of individuals
detected with Ad35-specific neutralizing antibodies observed
respectively, for Groups A–C (p= 0.08). Nevertheless, the
geometric mean titers among positive volunteers remained
relatively modest and were not significantly different among the
vaccination groups with geometric mean titers of 406, 31, 57 and
81 in Groups A–D, respectively. All placebo recipients tested
negative at each of the visits (data not shown). As reference, the
median Ad35 neutralizing titer among 6 potential study partici-
pants who had evidence of previous natural Ad35 infection at
study screening was 47.5 (range: 25–858). These subjects were not
enrolled into the study per protocol exclusion criteria (data not
shown).
HIV Serology at the End of the Study
At their last study visit, all 48 volunteers who remained in
follow-up (15 from the placebo group, 8 from Group A, 8 from
Group B, 9 from Group C, and 8 from Group D) were tested for
HIV. All volunteers tested negative for Abbott m2000 Real Time
PCR HIV-1 RNA. All placebo recipients and Group D volunteers
tested negative by ELISA (Bio-Rad Genetic Systems HIV 1/2 Plus
O EIA and Abbott Architect HIV Ab/Ag Combo EIA) and Bio-
Rad Genetic Systems HIV-1 Western Blot. In Groups A, B, and
C, respectively 25%, 38%, 78% of the volunteers tested positive
with HIV 1/2 Plus O EIA and 50%, 100% and 56% with Abbott
Architect HIV Ab/Ag Combo EIA.
Discussion
This study shows that Ad35-GRIN/ENV is safe and immuno-
genic when administered twice to Ad35-seronegative healthy
volunteers with doses from 26109 to 261011 vp. Reactogenicity
was dose-related with frequent moderate to severe systemic
symptoms consisting of headache, malaise and chills that began
within 12–24 hours of initial vaccination. All reactions were self-
limited and resolved within hours (systemic symptoms) to a few
days (injection site symptoms).
Ad35-GRIN/ENV at all dose levels was found to be
immunogenic, producing IFN-c ELISPOT responses in 90% of
all vaccinated individuals although the magnitude was relatively
modest to individual peptide pools. Anti-gp140 binding antibodies
were seen in all vaccine recipients in Groups A–C. The median
and range of Env and Nef ELISPOT responses were lower than
those seen to Gag, RT and Int and likely because the PFC assay is
less sensitive than the ELISPOT assay, we saw fewer responses to
Env and Nef. The IAVI-HIL ELISPOT assay has a positive cut off
value of 38 SFC per million PBMC. Assuming 50% of PBMC are
T cells, the 38 SFC value would equate to 0.0076% of CD3+ T
cells producing IFN-c. The median range of Env ELISPOT was
60–108 SFC per million PBMC across groups A–C which equates
to 0.012 to 0.0216% of CD3+ T cells responding. Such values are
below the limit of detection of our current ICS assay. Because of
the lower sensitivity of the PFC assays, responses at 2 weeks post-
2nd vaccination were less frequently positive than the IFN-c
ELISPOT assays, but indicated that the cellular response was
primarily mediated by CD8+ T lymphocytes and was typically
polyfunctional, with TNF-a and CD107 detected in addition to
IFN-c. A trend of a dose-response effect in the proportion of
subjects with positive IFN-c ELISPOT assays was seen after a
single injection (the small size of the study groups precluded an
assessment of statistical significance); however, the booster
vaccination at 6 months induced responses in nearly all the
participants in all groups. There was no clear indication of an
increase in magnitude or breadth (the latter by the number of
peptide pools recognized) in IFN-c ELISPOT responses by dose or
as a result of the 6-month booster immunization.
HIV gp140-specific binding antibodies were frequently seen
after the first immunization among recipients of the Ad35-GRIN/
Figure 5. Magnitude of HIV-specific antibodies. The geometric mean of a) anti-ENV Subtype A (UG037)- and b) anti-p24 (IIIB)-specific antibody
titers is shown at baseline, at 4 and 24 weeks post-first vaccination, and at 2, 14, 28, 40 and 48 weeks post-second vaccination.
doi:10.1371/journal.pone.0041936.g005
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ENV with a titer significantly increased with the 6-month boost in
all groups (p,0.0004), but declined appreciably within the
following 6 months. In addition, anti-Ad35 neutralizing antibodies
were induced at a low frequency and low titer after the first
immunization, but the 6-month boost increased the proportion of
responders significantly, particularly among those who received
the 261011 vp dose.
The presence of pre-existing Ad neutralizing antibodies and the
impact of such antibodies on reducing HIV-specific immune
responses after multiple immunizations remains a major concern
for the use of Ad vectors. In this study where volunteers enrolled
were all Ad35-specific neutralizing antibody negative at baseline,
we found that even after a second immunization with Ad35
vectors, Ad35-specific neutralizing antibody titers remained low,
regardless of the dose. HIV Env- and Gag-specific antibodies were
significantly boosted after the second immunization with modest
increases in cellular responses, suggesting that HIV-specific
cellular and humoral responses were not impacted by Ad35-
specific neutralizing antibodies induced by the first Ad35 vector
immunization. We cannot however exclude the interference of
cross-reactive preexisting Ad-specific T-cell immune responses on
the vaccine-induced T-cell responses [48]. The low prevalence and
titers of Ad35 compared with Ad5 neutralizing antibodies as well
as the induction of adequate cellular and humoral responses
shown in this study supports the use of Ad35 vectors in
heterologous or homologous prime-boost strategies [49].
This study also explored the potential phenomenon of an Env
immunodominance as suggested in animals [50,51,52] and other
human studies [53,54] by comparing IFN-c ELISPOT responses
with GRIN peptide pools between Group B and Group D (who
received 261010 vp of Ad35-GRIN/ENV or 161010 vp of Ad35-
GRIN, respectively). Although the small size of the groups
precluded firm conclusions, the frequency of positive IFN-c
ELISPOT assays in Group D appeared higher after the first
injection relative to Group B. Furthermore, overall, the magnitude
of positive responses was significantly higher in Group D
(vaccinated in the absence of Env genes) compared to Group B
for Gag, Pol/Int and Nef pools. There was insufficient evidence
from this small study to evaluate the mechanism of possible Env
interference, however as indicated above with the low Ad35
neutralization titers even after the second boost and at the highest
dose, we could not see an impact on insert specific immune
responses. Understanding how best to administer antigens to avoid
immunodominance, competition and the effects of pre-existing or
post immunization vector specific responses is an ongoing issue for
development of HIV, malaria, Cancer, TB and other vaccines
[55,56,57,58,59].
Interestingly, one study participant who received placebo in
this trial demonstrated IFN-c ELISPOT responses and anti-
gp140 binding antibody at baseline and all timepoints throughout
the trial in spite of testing negative in the licensed diagnostic kit
Abbott Architect HIV Ab/Ag Combo EIA at the University of
Rochester at study entry and negative HIV RNA levels. This
person did not disclose any behavior associated with high-risk for
HIV infection and had not participated in previous HIV vaccine
clinical trials. The reasons for these findings are still under
investigation.
This study adds to the accumulating literature of safe and
immunogenic candidate vaccines that could be included in
combination vaccine regimens. Similar to the Ad5 vector tested
in the Step Study, the Ad35 vector induced a high frequency of
HIV-specific CD8+ T-cell responses, however, our data suggests
that the Ad35-GRIN/ENV candidate induced a broader response
in terms of the number of protein regions recognized. In the
original Step study, 218 of 354 (62%) of individuals recognized two
to three HIV proteins with a median of 1 protein per person
[26,27]. Further assessment of the breadth of response was
performed in 72 subjects who participated in an earlier Phase I
trial of the same vaccine utilized in the Step study. In the latter
study, using mini-pools containing eight 9-amino acid (aa) peptides
spanning 16 aa of the vaccine sequence, the median (and mean) of
positive mini-pool responses per subject was 1 (1) for Gag, 1 (1) for
Nef and 2 (3) for Pol [60]. It is unclear what this may mean in
terms of potential vaccine efficacy, but the Step Study did show
evidence that vaccine-elicited T cells had an impact on the HIV-1
strains that established infection (a sieve effect) [61] and thus it is
reasonable to conclude that a broadened antiviral effect could be
beneficial. In addition, this study suggests that improved non-
envelope IFN-c ELISPOT responses may be induced if vaccina-
tion with Env proteins or Env encoding vectors are separated in
time or space.
As noted above, the community-based trial conducted in
Thailand (RV144) that employed a combination regimen of a
recombinant canarypox vector expressing HIV-1 gag, protease, env
genes boosted by a recombinant HIV-1 gp120 envelope protein
subunit showed protection against HIV acquisition however
without a measurable effect on viremia or the CD4+ T-cell count
in vaccinated and infected subjects. The vaccination regimen
induced modest levels of HIV-specific cellular immune responses,
mediated primarily by CD4+ T cells and high titers of HIV-
envelope specific binding antibodies [32]. The Step and RV144
results reinforce the need to develop new vaccines or vaccine
combinations able to induce more effective immune responses, in
particular at the mucosal level where HIV transmission events
occur [3]. Combination regimens using heterologous vectors in
prime-boost and inserts aiming at broadening CD4+ and CD8+
T-cell responses such as mosaics [62] and conserved sequences
[63] are promising avenues. Indeed, three other phase I clinical
trials, one with Ad35-GRIN in combination with an adjuvanted
core HIV protein vaccine (IAVI B002; NCT01264445), a second
with Ad35-ENV in combination with Ad26-ENVA (IAVI B003-
IPCAVD004-HVTN091; NCT01215149), both of which have
completed vaccinations, and a third with Ad35-GRIN/ENV in
prime-boost regimens with DNA administered by electroporation
and adjuvanted with IL-12 have been initiated (IAVI B004;
NCT01496989). These trials are designed to increase the breadth
in terms of epitope coverage, improving the CD4+ and CD8+ T-
cell responses and functional antibody responses. In spite of the
lack of HIV neutralizing antibodies, additional studies on the fine
specificity of the Env antibody response induced by Ad35-GRIN/
ENV are also warranted following the recent findings that IgG
binding antibody to a scaffolded HIV-1 gp120 V1V2 protein
encompassing the gut homing marker a4b7 integrin binding site
was identified in a post-hoc analysis as a correlate of risk for
acquisition of HIV infection in RV144 [64]. In conclusion, the
Ad35-GRIN/ENV candidate was generally well tolerated and
immunogenic at a dose of 261010 vp and has moved forward into
additional studies to further assess safety and immunogenicity and
should also be considered as a potential component of a regimen
tested in efficacy trials.
Supporting Information
Figure S1 Breadth of response by IFN-c ELISPOT
assay. The numbers inside the stacked bars represent the percent
of volunteers responding to 1, 2, 3, 4 or 5 different HIV-peptide
pools (Gag, RT, Pol/Int, Nef and Env) as indicated on the first
row of the X-axis. The second row of the X-axis shows the time
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point examined. The colors represent data from Groups A–D,
respectively. The inserted table shows the number of volunteers
per group at each time point that contributed ELISPOT data for
the bar graph.
(TIF)
Figure S2 Flow gating strategy. A. Quality control gating. A
time vs. CD4 QD605 is first applied to ensure acquisition of data
occurred without blockages and in this example to remove micro
aggregates formed by the CD4 QD605 antibody. Following this a
FSC-H vs. FSC-A gate is applied in order to exclude doublets and
cell clumps. Once the lymphocyte population is selected a dump
gate is applied to ensure that non-viable cells as well as B cells and
monocytes are excluded from analysis. A generous CD3 vs.
cytokine gate is applied to include any down-regulated antigen
specific cells. The example shown here is for IFN-c but all
cytokines are evaluated. B. CD4, CD8 and cytokine gating. The
CD4 and CD8 gates are applied in a similar manner, generous
CD4 and CD8 gates are applied vs. cytokine and contaminating
cells are removed subsequently by more stringent gating. Each
cytokine is gated vs. the opposite lineage and polyfunctional
responses are assessed using the Boolean function of FlowJo.
(TIF)
Figure S3 Ad35-specific neutralizing antibody titers
pre-vaccination, at 4 weeks post-first and 2 weeks
post-second vaccination. Each dot in the scatter plot
represents an individual Ad35 neutralization titer. EC90 titers
below the assay cut-off are plotted at the cutoff value of 16. At
each time point for each of the vaccine groups, the middle
horizontal bar shows the median value and the horizontal bars to
the top and bottom of the median represent the 75% and 25%
quartile values.
(TIF)
Tables S1 Frequency of local reactions per maximum severity
assessment.
(DOCX)
Table S2 Frequency of systemic reactions per maximum severity
assessment.
(DOCX)
Table S3 Median and range of positive IFN-c ELISPOT
responses (SFC/106 PBMC) across all visits.
(DOCX)
Table S4 CD4 and CD8 positive response rates to any antigen
by polychromatic flow cytometry.
(DOCX)
Table S5 Summary of antibody response frequencies.
(DOCX)
Protocol S1 Trial Protocol.
(PDF)
Checklist S1 CONSORT Checklist.
(DOC)
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